206 related articles for article (PubMed ID: 32886320)
41. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control.
Muijsers RB; Wagstaff AJ
Drugs; 2001; 61(15):2289-307. PubMed ID: 11772140
[TBL] [Abstract][Full Text] [Related]
42. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
43. Low doses of transdermal fentanyl in opioid-naive patients with cancer pain.
Mercadante S; Porzio G; Ferrera P; Aielli F; Adile C; Ficorella C
Curr Med Res Opin; 2010 Dec; 26(12):2765-8. PubMed ID: 21034376
[TBL] [Abstract][Full Text] [Related]
44. Exposure to Fentanyl After Transdermal Patch Administration for Cancer Pain Management.
Bista SR; Haywood A; Hardy J; Norris R; Hennig S
J Clin Pharmacol; 2016 Jun; 56(6):705-13. PubMed ID: 26381285
[TBL] [Abstract][Full Text] [Related]
45. [Three-day-type transdermal fentanyl patch conversion by rapid titration method with short-acting oral oxycodone for cancer pain].
Yamazaki K; Fujio N; Ishikawa N; Watanabe H; Kameyama M
Gan To Kagaku Ryoho; 2012 Mar; 39(3):405-8. PubMed ID: 22421768
[TBL] [Abstract][Full Text] [Related]
46. Transdermal fentanyl for cancer pain: Trial sequential analysis of 3406 patients from 35 randomized controlled trials.
Wang DD; Ma TT; Zhu HD; Peng CB
J Cancer Res Ther; 2018; 14(Supplement):S14-S21. PubMed ID: 29578144
[TBL] [Abstract][Full Text] [Related]
47. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
Clemens KE; Klaschik E
Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
[TBL] [Abstract][Full Text] [Related]
48. [Clinical study of one-day fentanyl patch in patients with cancer pain--evaluation of the efficacy and safety in relation to treatment switch from opioid analgesic therapy].
Hanaoka K; Yoshimura T; Tomioka T; Sakata H
Masui; 2011 Feb; 60(2):147-56. PubMed ID: 21384647
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain.
Shimoyama N; Gomyo I; Teramoto O; Kojima K; Higuchi H; Yukitoshi N; Ohta E; Shimoyama M
Jpn J Clin Oncol; 2015 Feb; 45(2):189-96. PubMed ID: 25378647
[TBL] [Abstract][Full Text] [Related]
50. Opioid plasma concentrations during a switch from transdermal fentanyl to methadone.
Mercadante S; Villari P; Ferrera P; Casuccio A; Gambaro V
J Palliat Med; 2007 Apr; 10(2):338-44. PubMed ID: 17472504
[TBL] [Abstract][Full Text] [Related]
51. A population-based study of transdermal fentanyl initiation in Australian clinical practice.
Gisev N; Pearson SA; Larance B; Larney S; Blanch B; Degenhardt L
Eur J Clin Pharmacol; 2019 Mar; 75(3):401-408. PubMed ID: 30392109
[TBL] [Abstract][Full Text] [Related]
52. A randomized controlled trial of postoperative analgesia following total knee replacement: transdermal Fentanyl patches versus patient controlled analgesia (PCA).
Hall MJ; Dixon SM; Bracey M; MacIntyre P; Powell RJ; Toms AD
Eur J Orthop Surg Traumatol; 2015 Aug; 25(6):1073-9. PubMed ID: 25753087
[TBL] [Abstract][Full Text] [Related]
53. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study.
Mercadante S; Porzio G; Ferrera P; Aielli F; Verna L; Tirelli W; Villari P; Casuccio A
Clin Ther; 2009 Oct; 31(10):2134-8. PubMed ID: 19922884
[TBL] [Abstract][Full Text] [Related]
54. Initial dose cascade of TTS fentanyl with proper adjuvant medications in cancer pain.
Baik SW; Kim KH; Kim YC; Lee SC; Kim DK; Jung JE
J Korean Med Sci; 2003 Oct; 18(5):733-7. PubMed ID: 14555829
[TBL] [Abstract][Full Text] [Related]
55. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
[TBL] [Abstract][Full Text] [Related]
56. Controlled-release oxycodone tablets after transdermal-based opioid therapy in patients with cancer and non-cancer pain.
Ravera E; Di Santo S; Bosco R; Arboscello C; Chiarlone R
Aging Clin Exp Res; 2011; 23(5-6):328-32. PubMed ID: 22526067
[TBL] [Abstract][Full Text] [Related]
57. Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: results of a compassionate-use study with special focus on elderly patients.
Menten J; Desmedt M; Lossignol D; Mullie A
Curr Med Res Opin; 2002; 18(8):488-98. PubMed ID: 12564660
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of a six-hour continuous overlap method for converting intravenous to transdermal fentanyl in cancer pain.
Samala RV; Bloise R; Davis MP
J Pain Symptom Manage; 2014 Jul; 48(1):132-6. PubMed ID: 24291296
[TBL] [Abstract][Full Text] [Related]
59. A safe and effective method for converting patients from transdermal to intravenous fentanyl for the treatment of acute cancer-related pain.
Kornick CA; Santiago-Palma J; Schulman G; O'Brien PC; Weigand S; Payne R; Manfredi PL
Cancer; 2003 Jun; 97(12):3121-4. PubMed ID: 12784350
[TBL] [Abstract][Full Text] [Related]
60. Cancer Cachexia May Hinder Pain Control When Using Fentanyl Patch.
Chiba T; Takahashi H; Tairabune T; Kimura S; Ueda H; Kudo K
Biol Pharm Bull; 2020; 43(5):873-878. PubMed ID: 32378563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
